Centralized procurement of Chinese patent medicines and formula particles may start, starting with high-priced and large-volume varieties

On August 9, the National Medical Insurance Administration issued the "Response of the National Medical Insurance Administration to Recommendation No. 4126 of the Fourth Session of the Thirteenth National People's Congress", in response to the National People's Congress representative Lu Qingguo's "Regarding Accelerating the Entry of Chinese Medicines and Formula Granules into Centralized Procurement" Suggestion" question.

The National Medical Insurance Bureau pointed out in this "Reply", "Your suggestion to bring proprietary Chinese medicines into centralized drug procurement as soon as possible, so that more traditional Chinese medicine manufacturers can participate in the competition fairly, we have policy arrangements and preliminary explorations. "The State Council" The General Office's Opinions on Promoting the Normalization and Institutionalization of Drug Centralized and Volume Procurement (Guobanfa [2021] No. 2) clearly stated,'Explore the combined development of centralized drug delivery for different generic drugs with similar indications or functions and indications. Purchasing provides basic guidelines for the centralized procurement of proprietary Chinese medicines. At present, Qinghai Province, Jinhua, Zhejiang, Puyang, Henan and other places have carried out centralized procurement exploration for some varieties of proprietary Chinese medicines with high demand and high amounts, and positive results have been achieved."